Someone asked me recently if donated kidneys last forever. It’s been 17 years and a few days since I received one, which has lasted 17 years longer than I thought it would. That may not be forever, but we’re doing pretty well so far.
None of it would be possible without medical advancements.
It seems like a lifetime ago. I was in college, I lived in New Mexico, and I had a different last name. I went to hemodialysis three times a week, worked part time, went to school full time and lived in a small garden apartment with my sister.
There were also lots of health complications because dialysis, while lifesaving, is not particularly good at keeping you healthy for any significant length of time. When you have terrible veins from a lifetime of kidney disease (which means many surgeries to identify and fix dialysis access points), a tendency toward infections and pneumonias and a brand new seizure disorder, dialysis is particularly troublesome. Add it all up, and what you get is someone who, had I not gotten the call that there was a kidney for me, would probably not have survived all that much longer.
But I did get the call. It came at about 10pm Mountain Time on Sunday, March 12. They called and told me to be prepared to come to the hospital, but not to leave yet. They would call me back in an hour and confirm whether I needed to actually get to the hospital or not. They called back, and off I went.
The next day, I received the kidney from a woman named Michelle, who was in a tragic car accident and did not survive. Her parents made the decision to look outside their grief and save someone else’s child. The person they saved happened to be me.
Right away there were problems. My body was rejecting the kidney. The anti-rejection drugs available at the time weren’t working. I was retaining a life-threatening amount of fluid, and the pain I was in was beyond comprehension. I seemed destined for either a major disappointment or worse.
Then medical advancements stepped in. My doctor suggested a (new-at-the-time) procedure for newly transplanted patients, apheresis, to remove the blood from my body, separate the blood into plasma and cells and then reintroduce the cells into my body after removing the antibodies that were rejecting my transplanted kidney. It worked.
Over the years, there have been many times that medical technology has stepped in and worked its magic. There are the daily examples and those I would have hoped to never experience. From the antirejection drugs I take every single day that have kept this kidney working for 17 years, to the antibiotics I take to avoid and treat inevitable infections, to the antivirals that were needed to combat a vicious virus that would have otherwise destroyed my kidney less than two years after I received it.
Each and every one of these medical advancements has led me here, 17 years later, and science willing, many, many more.
Priscilla VanderVeer
is former Vice President, Public Affairs, where she led the development, execution and management of public affairs and communications strategies and activities for PhRMA’s key state, federal and international advocacy priorities. She has more than two decades of experience communicating important health care issues to a wide variety of audiences, including medical, health and patient advocates, policymakers, opinion-leaders and the public.
Priscilla VanderVeer
CMS’ MFN proposals won’t help seniors despite lofty promises
Voters voice concerns on government price controls
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Recognizing National Glaucoma Awareness Month
In their own words: Insured Americans support policy reforms that address access and affordability concerns
Navigating the patient experience: Burdens and barriers standing between patients and their care
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Myth vs. Fact: The Senate’s latest price setting proposal
ICYMI: Patients across the country are sharing concerns about government price setting
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
The Patient Perspective: Government price-setting harms patients
Spotlighting a growing mental health challenge
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
Getting the 340B program back on track in 2021
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
PhRMA comments to administration on Medicare Part D proposed rule
Keep the Six Protected Classes, protected
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
How much do you know about Medicare Part B?
How ICER’s assessment of a new class of migraine treatments fails patients
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
New report shows over 500 medicines in development for neurological disorders
Fact Check Friday: The truth about the cost of 340B to patients
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Medicare Monday: A discussion on affordability and access to medicines
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
Biopharmaceutical industry’s success reducing disparities for African Americans
17 years (and more) of medical discoveries
Kidney Disease
Patients
17 years (and more) of medical discoveries
17 years (and more) of medical discoveries